Aldesleukin
- Generic Name
- Aldesleukin
- Brand Names
- Proleukin
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 110942-02-4
- Unique Ingredient Identifier
- M89N0Q7EQR
- Background
Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This recombinant form differs from native in...
- Indication
For treatment of adults with metastatic renal cell carcinoma.
- Associated Conditions
- Metastatic Melanoma, Metastatic Renal Cell Carcinoma ( mRCC)
- Associated Therapies
- -
Single Patient Protocol: A Phase II Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in a Patient With Metastatic Cancer Plus the Administration of Pembrolizumab
Low Dose IL-2 Therapy in Patients With a Depressive Episode in the Course of a Bipolar Disorder
- First Posted Date
- 2019-10-21
- Last Posted Date
- 2023-08-08
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 15
- Registration Number
- NCT04133233
- Locations
- 🇫🇷
Pr Marion Leboyer, Créteil, Hôpital Albert Chenevier, France
Non-Viral TCR Gene Therapy
- First Posted Date
- 2019-09-25
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT04102436
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Low-dose IL-2 to the Kinetics of Regulatory T-cell in Healthy Volunteers
- First Posted Date
- 2019-02-11
- Last Posted Date
- 2021-12-30
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 40
- Registration Number
- NCT03837093
- Locations
- 🇫🇷
Clinical Investigation Center Paris Est Hôpital Universitaire Pitié-Salpêtrière 83 bd de l'Hôpital 75013 Paris, Paris, France
Interleukin-2 Therapy of Autoimmunity in Diabetes (ITAD)
- First Posted Date
- 2018-12-20
- Last Posted Date
- 2021-12-16
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 41
- Registration Number
- NCT03782636
- Locations
- 🇬🇧
Bristol Royal Hospital for Children, Bristol, United Kingdom
🇬🇧Nottingham Children's Hospital, Nottingham, United Kingdom
🇬🇧The Great North Children's Hospital, Newcastle Upon Tyne, United Kingdom
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients
- First Posted Date
- 2018-11-19
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 70
- Registration Number
- NCT03745326
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- Conditions
- Platinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Ovarian CarcinomaPlatinum-Resistant Primary Peritoneal CarcinomaRecurrent Fallopian Tube CarcinomaRefractory Ovarian CarcinomaPlatinum-Sensitive Ovarian CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal CarcinomaRefractory Primary Peritoneal CarcinomaRefractory Fallopian Tube Carcinoma
- Interventions
- First Posted Date
- 2018-10-01
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 4
- Registration Number
- NCT03691376
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Immunotherapy for the Treatment of Advanced Solid Tumor
- Conditions
- Interventions
- First Posted Date
- 2018-09-05
- Last Posted Date
- 2024-08-13
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT03658785
- Locations
- 🇨🇳
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas
- Conditions
- Interventions
- First Posted Date
- 2018-02-28
- Last Posted Date
- 2024-11-29
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT03449108
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-01-29
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 270
- Registration Number
- NCT03412877
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.